A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2018
At a glance
- Drugs Galinpepimut S (Primary) ; Nivolumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 05 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 05 Mar 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 05 Mar 2018 Status changed from recruiting to active, no longer recruiting.